Clinical Trials
13 trialsNCT00006022 2015-12-14
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00003993 2015-04-29
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003174 2014-04-24
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00004144 2014-04-24
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00003108 2013-07-18
Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003242 2013-06-24
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00112476 2013-05-03
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00022555 2013-01-25
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003166 2013-01-11
Bryostatin and Vincristine in B-Cell Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00012376 2013-01-09
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003132 2012-11-09
Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer
NYU Langone Health
Phase 1 Completed
NCT00005580 2010-02-24
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
Virginia Commonwealth University
Phase 1 Completed
NCT00003079 2010-02-17
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
Virginia Commonwealth University
Phase 1 Completed